Skip to main content

Research Repository

Advanced Search

18 F-Fluorodeoxyglucose PET/CT and dynamic contrast-enhanced MRI as imaging biomarkers in malignant pleural mesothelioma

Hall, David O; Hooper, Clare E; Searle, Julie; Darby, Michael; White, Paul; Harvey, John E; Braybrooke, Jeremy P; Maskell, Nick A; Masani, Vidan; Lyburn, Iain D

18 F-Fluorodeoxyglucose PET/CT and dynamic contrast-enhanced MRI as imaging biomarkers in malignant pleural mesothelioma Thumbnail


Authors

David O Hall

Clare E Hooper

Julie Searle

Michael Darby

Paul White Paul.White@uwe.ac.uk
Professor in Applied Statistics

John E Harvey

Jeremy P Braybrooke

Nick A Maskell

Vidan Masani

Iain D Lyburn



Abstract

© 2018 Wolters Kluwer Health, Inc. All rights reserved. Purpose The purpose of this study was to compare the use of fluorine-18-fluorodeoxyglucose (18 F-FDG) PET with computed tomography (CT) and dynamic contrast-enhanced (DCE) MRI to predict prognosis and monitor treatment in malignant pleural mesothelioma. Patients and methods 18 F-FDG PET/CT and DCE-MRI studies carried out as part of the South West Area Mesothelioma Pemetrexed trial were used. 18 F-FDG PET/CT and DCE-MRI studies were carried out before treatment, and after two cycles of chemotherapy, on patients treated with pemetrexed and cisplatin. A total of 73 patients were recruited, of whom 65 had PET/CT and DCE-MRI scans. Baseline measurements from 18 F-FDG PET/CT (maximum standardized uptake value, metabolic tumour volume and total lesion glycolysis) and DCE-MRI (integrated area under the first 90s of the curve and washout slope) were compared with overall survival (OS) using Kaplan-Meier and Cox regression analyses, and changes in imaging measurements were compared with disease progression. Results PET/CT and DCE-MRI measurements were not correlated with each other. Maximum standardized uptake value, metabolic tumour volume and total lesion glycolysis were significantly related to OS with Cox regression analysis and Kaplan-Meir analysis, and DCE-MRI washout curve shape was significantly related to OS. DCE-MRI curve shape can be combined with 18 F-FDG PET/CT to give additional prognostic information. Changes in measurements were not related to progression-free survival. Conclusions 18 F-FDG PET/CT and DCE-MRI give prognostic information in malignant pleural mesothelioma. Neither PET/CT nor DCE-MRI is useful for monitoring disease progression.

Journal Article Type Article
Acceptance Date Nov 27, 2017
Publication Date Jan 1, 2018
Deposit Date Jan 19, 2018
Publicly Available Date Jan 24, 2018
Journal Nuclear Medicine Communications
Print ISSN 0143-3636
Electronic ISSN 1473-5628
Publisher Lippincott, Williams & Wilkins
Peer Reviewed Peer Reviewed
Volume 39
Issue 2
Pages 161-170
DOI https://doi.org/10.1097/MNM.0000000000000789
Keywords 18F-Fluorodeoxyglucose, PET/CT, dynamic, contrast-enhanced, MRI, imaging biomarkers, malignant, pleural mesothelioma
Public URL https://uwe-repository.worktribe.com/output/874224
Publisher URL https://journals.lww.com/nuclearmedicinecomm/Citation/2018/02000/18F_Fluorodeoxyglucose_PET_CT_and_dynamic.10.aspx
Additional Information Additional Information : This is the author's accepted manuscript. The final, published version is available at https://journals.lww.com/nuclearmedicinecomm/Citation/2018/02000/18F_Fluorodeoxyglucose_PET_CT_and_dynamic.10.aspx
Contract Date Jan 24, 2018